03/18/23 2:10 PMOTC : UCBJY clinical trialBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksUCB, a global biopharmaceutical company, today announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa. 1 Data from the two studies showed that bimekizumab achieved...RHEA-AIvery positive
03/16/23 7:00 AMOTC : UCBJY conferencesUCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis SuppurativaUCB, a global biopharmaceutical company, today announced that itRHEA-AInegative
01/18/23 7:00 AMOTC : UCBJY clinical trialAnnals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial SpondyloarthritisUCB, a global biopharmaceutical company, today announced thatRHEA-AIneutral
01/06/23 7:00 AMOTC : UCBJY UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority ReviewBiologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetycholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive RozanolixizumabRHEA-AIneutral
12/09/22 7:00 AMOTC : UCBJY clinical trialUCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis SuppurativaTop-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical relevance First Phase 3 evidence to suggest that targeting IL-17F in addition to IL-17A may be a promising treatmentRHEA-AIpositive
12/07/22 7:00 AMOTC : UCBJY clinical trialThe Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic ArthritisUCB, a global biopharmaceutical company,RHEA-AIneutral
12/01/22 7:00 AMOTC : UCBJY conferencesUCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment to improving the lives of people living with epilepsy New data include insights into the efficacy and safety profile of BRIVIACT ® (brivaracetam) CV, FINTEPLA ® (fenfluramine)RHEA-AIneutral
11/23/22 7:00 AMOTC : UCBJY Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA ® in LGS provide significant reduction in the frequency of multiple seizure types associated with a drop or fall for 15 months, including tonic and generalized tonic-clonic seizures 1 The cardiovascular safety in thisRHEA-AIneutral
11/14/22 7:00 AMOTC : UCBJY UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patientsNew drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food and Drug Administration (FDA) follows the recent European Medicines Agency (EMA)RHEA-AIneutral
11/10/22 7:00 AMOTC : UCBJY clinical trialBimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing SpondylitisNew late-breaking 52-week data from Phase 3 bimekizumab investigational studies in psoriatic arthritis and across the spectrum of axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis, presented at ACR Convergence 2022 In BE OPTIMAL, clinical jointRHEA-AIpositive